1. The pharmacokinetics of the two enantiomers of terbutaline, (+)T and (-)T, and the racemate (+/-)T, have been evaluated after single intravenous and oral dosage to six healthy volunteers. 2. The mean systemic clearance, CL, was 0.19 and 0.13 l h-1 kg-1 for (+)T and (-)T, respectively. This difference was statistically significant. The mean clearance of (+/-)T was 0.20 l h-1 kg-1. Volumes of distribution were similar (1.9 l kg-1) after the three intravenous administrations. The differences in CL were reflected in values of the elimination half-life and MRT. 3. The difference in CL of the isomers could be explained by a corresponding difference in their renal clearance, CLR. Competition for stereoselective active reabsorption in the tubule might explain why (+)T seemed to enhance the CLR of (-)T when the drug was given as the racemate. 4. Oral bioavailability, calculated from plasma data, of (+)T was 7.5% and that of (-)T was 14.8%. This difference was statistically significant and was mainly due to a difference in absorption of (+)T and (-)T, but also to a difference in their subsequent first-pass metabolism. The bioavailability of (+/-)T was similar to that of (-)T. 5. (-)T appears to govern the absorption properties of the racemate, while (+)T determines its elimination behaviour. Systemic metabolism of the two enantiomers was similar and, therefore, a greater first-pass metabolism of (+)T would reflect a higher capacity of the gut wall to metabolise this isomer.
展开▼
机译:1.在对六名健康志愿者进行单次静脉内和口服给药后,已评估了特布他林的两种对映体(+)T和(-)T以及外消旋体(+/-)T的药代动力学。 2.(+)T和(-)T的平均全身清除率CL分别为0.19和0.13 l h-1 kg-1。这种差异具有统计学意义。 (+/-)T的平均清除率为0.20 l h-1 kg-1。在三次静脉内给药后,分布体积相似(1.9 l kg-1)。 CL的差异反映在消除半衰期和MRT值上。 3.异构体的CL差异可以通过其肾脏清除率CLR的相应差异来解释。小管中立体选择性主动重吸收的竞争可能解释了为什么当药物以外消旋体形式给药时,(+)T似乎会增强(-)T的CLR。 4.根据血浆数据计算,(+)T的口服生物利用度为7.5%,(-)T的口服生物利用度为14.8%。这种差异具有统计学意义,主要是由于(+)T和(-)T的吸收差异,也归因于其随后的首过代谢的差异。 (+/-)T的生物利用度类似于(-)T的生物利用度。 5.(-)T似乎决定了外消旋物的吸收性能,而(+)T决定了其消灭行为。两种对映异构体的全身代谢相似,因此,(+)T的较大的首过代谢将反映出肠壁更高的代谢这种异构体的能力。
展开▼